Anticoagulation for non-valvular atrial aibrillation - Towards a new beginning with ximelagatran

Current Controlled Trials in Cardiovascular Medicine

Volumn 5, Issue , 2004, Pages

  Boos, Christopher J ^a   More, Ranjit S ^b  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b BLACKPOOL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINOTRANSFERASE; PLACEBO; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; DATA ANALYSIS; DRUG ABSORPTION; DRUG USE; EVIDENCE BASED MEDICINE; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; LIVER FUNCTION; LIVER TOXICITY; PATIENT MONITORING; REVIEW; RISK ASSESSMENT; STROKE;

EID: 17444410951     PISSN: 14686694     EISSN: 14686694     Source Type: Journal    
DOI: 10.1186/1468-6708-5-3     Document Type: Review

References (69)

1. Prystowsky EN, Benson DW Jr, Fuster V, Hart RG, Kay GN, Myerburg RJ, Naccarelli GV, Wyse DG: Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Eletrophysiology, American Heart Association. Circulation 1990, 93:1262-1277.
2. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Woll: Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994, 271:840-844.
3. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG: Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med 1995, 155:469-473.
4. Braunwald E: Shattuck lecture - Cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997, 337,:1360-1369.
5. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the An Ticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001, 285:2370-2375.
6. Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB: Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978, 28:973-977.
7. Villani GQ, Piepoli PE, Villani PE, Capuci A: Anticoagulation in atrial fibrillation: what is certain and what is to come. Ear Heart J 2003, Suppl H:45-50.
8. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE: Antithrombotic therapy in atrial fibrillation. Chest 2001, Suppl 1:194-206.
9. Wolf PA, Abbot RD, Kannel WB: Atrial fibrillation as an independent risk for stroke: the Framingham Study. Stroke 1991, 22:983-988.
10. Peterson P, Boysen G, Gofriedsen J, Andersen ED, Anderson B: Placebo controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet 1989, 1:175-179.
11. Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation 1991, 84:527-539.
12. The Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF) Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990, 323:1505-1511.
13. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJ: Warfarin in the prevention of stroke associated with non-rheumatic atrial fibrillation (SPINAF), N Engl J Med 1992, 327:1406-1412.
14. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C: Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991, 18:349-355.
15. Atrial Fibrillation Investigators. Risk factors for stroke and efficiency of antithrombotic therapy in atrial fibrillation analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994, 154:1449-1457.
16. European Atrial Fibrillation (EAFT) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993, 342:1255-1262.
17. Diener HC Lowenthal A: Antiplatelet therapy to prevent stroke: risk a brain hemmorrhage and efficacy in atrial fibrillation. J Neurol Sci 1997, 153:112.
18. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study (ESPS) 2. Dipyridamole and acetyisalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996, 143:1-13.
19. Posada IS, Barriales V: Alternate - day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group. Am Heart J 1999, 138:137-143.
20. Benavente O, Hart R, Koustaal P, Laupacis A, McBride R: Antiplatelet therpay for preventing stroke in patients with non-valvular atrial fibrilation and no previous history of stroke or transient ischemic attacks. In Warlow C, Yan Gijn J, Sandercock P, eds. St. oke Module of the Cochrane Database of Systematic Reviews. Oxford: The Cochrane Collaboration 1999.
21. Hart RG, Benavente O, McBride R, Pearce LA: Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999, 131:492-1501.
22. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation. Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994, 343:687-691.
23. Gullov AL, Koeloed BG, Petersen P, Pedersen TS, Andersen ED, Godtfredsen J, Boysen G: Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibriliation, Aspirin, and Anticoagulation Study. Arch Intern Med 1998, 158:1513-1521.
24. Hellemons BS, Langenberg M, Lodder J, Vermeer F, Schouten HJ, Lemmens TG van Ree JW, Knottnerus JA: Primary prevention of arterial thromboembolism in nonrheumatic atrial fibrillation: the PATAF trial study design. Control Clin Trials 1999, 20:386-393.
25. Atrial Fibrillation Investigators. Adjusted-dose warfarin vs low-intensity, fixed-close warfarin plus aspirin for high risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet 1996, 348:633-638.
26. Fuster V, Rycen LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Cregorators G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC, Klein WW, Alonso-Garcia A, Blomstrom-Lundqvist C, De Backer G, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A: American College of Cardiology/American Heart Association/European Society of Cardiology Board: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation: developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001, 38:1231-1266.
27. Laupacis A, Albers G, Dalen J, Dunn MI, Jacobson AK, Singer DE: Antithrombotic therapy in atrial fibrillation. Chest 1998, 114(5 Suppl):579S-589S.
28. Optimal oral anticoagulant therapy in patients with non-rheumatic atrial fibrillation and recent cerebral ischemist. The European Atrial Fibrillation Trial Study Group. N Engl J Med 1995, 333:5-10.
29. Connolly SJ: Preventing stroke in patients with atrial fibrillation: current treatments and new concepts. Am Heart J 2003, 145:418-423.
30. Jaffer A, Bragg L: Practical tips for warfarin dosing and monitoring. Cleve Clin J Med 2003, 70:361-371.
31. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D, Brandt JT: Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1998, 114(5 Suppl):445S-469S.
32. Hylek EM, Skates SJ, Sheehan MA, Singer DE: An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996, 335:540-546.
33. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE: Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003, 349:1019-1026.
34. Hylek EM, Singer DE: Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994, 120:897-902.
35. Ibrahim SA, Kwoh CK: Underutilization of oral ant coagulant therapy for stroke prevention in elderly patients with heart failure. Am Heart J 2000, 140:219-220.
36. Brass LM, Krumholz HM, Scinto JM, Radford M: Warfarin use among patients with atrial fibrillation. Stroke 1997, 28:2382-2389.
37. Whittle J, Wickenheiser L, Venditti LN: Is warfarin underused in the treatment of elderly persons with atrial fibrillation? Arch Intern Med 1997, 157:441-445.
38. Ibrahim SA, Kwoh CK: Underutilization of oral anticoagulant therapy for stroke prevention in elderly patients with heart failure. Am Heart J 2000, 140:219-220.
39. Buckingham TA, Hatala R: Anticoagulants for atrial fibrillation: why is the treatment rate so low? Clin Cardiol 2002, 25:447-454.
40. Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT: Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000, 160:41-46.
41. Bungard TJ, Ackman ML, Ho G, Tsuyuki RT: Adequacy of anticoagulation in patients with atrial fibrillation coming to a hospital. Pharmacotherapy 2000, 20:1060-1065.
42. Laupacis A: Anticoagulant-related bleeding in order persons with atrial fibrillation: physicians' fears often unfounded. Arch Intern Med 2003, 163:1580-1586.
43. Levine MN, Raskob G, Landefeld S, Kearon C: Hemorrhagic complications of anticoagulant treatment. Chest. 2001, Suppl 1:108-121.
44. Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A: Antithrombotic therapy in atrial fibrillation. Chest 1995, 108(4 Suppl):352S-359S.
45. Sebastian JL, Tresch DD: Use of oral anticoagulants in older patients. Drugs Aging 2000, 16:409-435.
46. Hopfner R: Ximelagatran (AstraZeneca). Curr Opin Investig Drugs 2002, 3:246-251.
47. Gustafsson D, Elg M: The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res 2003, Suppl 1:9-15.
48. Samama MM, Gerotziafas GT, Elalamy I, Horellou MH, Conard J: Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb 2002, 32:218-224.
49. Eriksson UG, Bredberg U, Gislen K, Johansson LC, Frison L, Ahnoff M, Gustafsson D: Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol 2003, 59:35-43.
50. Johansson LC, Frison F, Logren U, Fager G, Gustafsson D, Eriksson UG: Influence of age on the pharmacokinetics and pharmacodynamics on ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 2003, 42:381-392.
51. Sarich TC, Teng F, Peters GR, Wollbratt M, Homolka R, Svensson M, Eriksson UG: No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran. Clin Pharmacokinet 2003, 42:485-492.
52. Johansson LC, Andersson M, Fager G, Gustafsson D, Eriksson UG: No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers. Clin Pharmacokinet 2003, 42:475-484.
53. Bredberg E, Andersson TB, Frison L, Thuresson A, Johansson S, Eriksson-Lepkowska N, Larsson M, Eriksson UG: Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. Clin Pharmacokinet 2003, 42:765-777.
54. Wahlander K, Eriksson-Lepkowska M, Frison L, Fager G, Eriksson UG: No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 2003, 42:755-64.
55. Eriksson U, Johansson S, Attman PO, Mulec H, Frison L, Fager G, Samuelsson O: Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. Clin Pharmacokinet 2003, 42:743-753.
56. Petersen P, Grind M, Adler J: SPORTIF II Investigators. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability and safety study. J Am Coll Cardiol 2003, 41:1445-1451.
57. Halperin JL: Executive Steering Committee, SPORTIF III and V Study Investigations Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003, 146:431-8.
58. Olsson SB: Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003, 362:1691-1698.
59. Halperin JL: Efficacy and Saftey Study of Oral Direct Thrombin Inhibitor Ximelagatran Compared with Dose-Adjusted Warfarin in the Prevention of Stroke and Systemic Embolic Events in Patients with Atrial Fibrillation (SPORTIF V) American Heart Association Scientific sessions. Proceedings of the American Heart Association: Florida. 9-12 Nov 2003.
60. Schulman S, Wanlancer K, Lundström T, Clason SB, Eriksson H: THRIVE II. Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003, 349:1713-1721.
61. Francis CW Berkowicz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, Peters GR, Roth AW, McElnattan J, Colwell CW Jr: EXULT A Study Group. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total kne-replacement. N Engl J Med 2003, 349:1703-1712.
62. Wallentin L, Wilcox RG, Weaver WD, Emanuelsson H, Goodvin A, Nystrom P, Bylosk A: ESTEEM Investigators Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003, 362:789-797.
63. Eriksson H, Wallander K, Gustafsson D, Welin LT, Frison L, Schulman S: Thrive Investigators. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003, 1:41-47.
64. Glynn O: The EXPRESS (EXpanded PRophylaxis Evaluation. Surgery Study) preliminary results. Int J Clin Pract 2003, 57:57-59.
65. Hamaad A, Tayebjee MH, Lip GY: The METHRO (MElagatran for THRombin inhibition in Orthopaedic surgery) trials. Expert Opin Investig Drugs 2003, 12:865-870.
66. Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Ginsberg JS, Lieberman JR, Webster AK, Whipple JP, Peters GR, Colwell CW Jr. Ximelagatran versus warfarin for the prevention of venols thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med 2002, 137:648-655.
67. Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, Jensvold NG, Selby JV, Singer DE: Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003, 290:2685-2692.
68. Sunderji R, Fung A, Gin K, Shalansky K, Carter C: Patient self-management of oral anticoagulation: a review. Can J Cardiol 2003, 19:931-5.
69. Koertke H, Minami K, Boethig D, Breymann T, Seifert D, Wagner O, Atmacha N, Krian A, Ennker J, Taborski U, Klovekorn WP, Moosdorf R, Saggau W, Koerfer R: INR self-management permits lower anticoagulation levels after mechanical heart valve replacement. Circulation 2003, 108(1 Suppl II):75-8.